TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21175981
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin infusion (Actrapid 2 IU/h) during dialysis
Study: 15095806
Drug: Auditory, tactile,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory, tactile, visual, and vestibular (ATVV) multisensory intervention twice daily from 33 weeks postconceptional age until hospital discharge
Study: 2198303
Drug: Buspirone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (15 mg/day, titrated to a maximum of 90 mg/day)
Study: 2198303
Drug: Buspirone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (40 mg/day)
Study: 30409085
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet with 3-4 daily serves of dairy food (MedDairy)
Study: 30905230
Drug: Canola oil
Normalized name: Canola Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canola oil (20 mL/d)
Study: 30905230
Drug: Amaranth oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amaranth oil (20 mL/d)
Study: 24057101
Drug: Dexamethasone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.2 mg/kg intravenous before anesthesia)
Study: 11317194
Drug: COER-verapamil (180-540
Approvals — FDA: no, EMA: no, PMDA: no
Description: COER-verapamil (180-540 mg at bedtime)
Study: 7805631
Drug: Behavioral family-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral family-based treatment targeting parents and children for weight loss
Study: 26160319
Drug: Intravenous midazolam-fentanyl
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam-fentanyl anaesthesia (Control)
Study: 19081414
Drug: Transradial PCI
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transradial PCI with maximal antiplatelet therapy (clopidogrel and abciximab)
Study: 16572442
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg infliximab
Study: 9231892
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of verapamil slow release (SR) and trandolapril, administered for 8 weeks
Study: 3884766
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment (prednisone plus azathioprine)
Study: 31004493
Drug: Progressive multi-component
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive multi-component (PMC) intervention including lower extremity resistance training at 80% of a 1-repetition maximum, task-specific activities of daily living training, advanced gait and balance training, nutritional supplementation, and nursing support during transition from hospital to home
Study: 31004493
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC) physical therapy
Study: 30348145
Drug: GLP-1 RA
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GLP-1 RA therapy
Study: 28002471
Drug: Omeprazole 2.5
Normalized name: omeprazole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 2.5 mg/kg/day for neonates born at less than 32 weeks of GA (n = 30)
Study: 28002471
Drug: Omeprazole 1
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 1 mg/kg/day for neonates born at more than 32 weeks of GA (n = 24)
Study: 16368032
Drug: Psychological interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological interventions (cognitive behaviour therapy, counselling)
Study: 12163777
Drug: Early hemodynamic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early hemodynamic optimization (goals: cardiac index >4.5 L x min(‐1) x m(‐2), pulmonary artery occlusion pressure <18 mm Hg, oxygen delivery >600 mL x min(‐1) x m(‐2), oxygen consumption >170 mL x min(‐1) x m(‐2))
Study: 12163777
Drug: Normal values
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal values as goals or therapy that did not improve oxygen delivery
Study: 9797239
Drug: 1% cidofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% cidofovir gel
Study: 9797239
Drug: 3% cidofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% cidofovir gel
Study: 9797239
Drug: 5% cidofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% cidofovir gel
Study: 7705123
Drug: Mesna (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesna (3 mL)
Study: 7705123
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (3 mL)
Study: 2768152
Drug: Methylphenidate (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (highest dose)
Study: 2768152
Drug: Methylphenidate (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (lower dose)
Study: 861124
Drug: Nitrazepam 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam 2.5 mg
Study: 27613951
Drug: Combustible Cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combustible Cigarettes (CC)
Study: 23541711
Drug: 3.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg Zolpidem Sublingual Tablet (ZST)
Study: 23541711
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Immediate-Release (IR) Oral Zolpidem
Study: 19074594
Drug: Candesartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (angiotensin II type 1 receptor antagonist)
Study: 15119520
Drug: Outpatient strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient strategy using low‐molecular‐weight heparin, dalteparin, administered subcutaneously once daily, adjusted for body weight.
Study: 15119520
Drug: Inpatient strategy
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient strategy using low‐molecular‐weight heparin, dalteparin, administered subcutaneously once daily, adjusted for body weight.
Study: 10665615
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate 600 mg/wk
Study: 7984574
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies OKT-4 and OKT-8 used in tuberculous patients
Study: 30571562
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of angiotensin-converting enzyme inhibitor-based therapy
Study: 25251676
Drug: ADF-L (lunch)
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADF-L (lunch)
Study: 21164045
Drug: Curcumin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin group (10 participants) ingested 8 g of curcuminoids (C(3)‐Complex) with 16 oz of bottled water.
Study: 18066139
Drug: Protein-source tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protein-source tryptophan (deoiled gourd seed) in combination with carbohydrate
Study: 11295690
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (low-dose warfarin sodium and aspirin)
Study: 27064030
Drug: Drospirenone (DRP)‐containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone (DRP)‐containing COCs, combined with metformin (1.5 g/d) and lifestyle modifications
Study: 27064030
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA)‐containing COCs, combined with metformin (1.5 g/d) and lifestyle modifications
Study: 24637997
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with chemotherapy (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks)
Study: 20521348
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (four cycles of carboplatin and paclitaxel)
Study: 17517949
Drug: pyrimethamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrimethamine (50 mg/day) plus sulfadiazine (4 g/day) and folinic acid (25 mg/day)
Study: 17517949
Drug: trimethoprim (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim (10 mg/kg/day) plus sulfamethoxazole (50 mg/kg/day) (TMP‐SMX)
Study: 12792513
Drug: Vitamin supplementation
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplementation (folic acid 5 mg/day; vitamin B(6) 50 mg/day; vitamin B(12) 400 microg)
Study: 10676599
Drug: Intravenous Optison®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Optison® (FS069) at 0.5 ml
Study: 10676599
Drug: Intravenous Optison®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Optison® (FS069) at higher doses (0.2, 3.0, and 5.0 ml)
Study: 8800113
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of high dose furosemide (mean daily dosage 690 mg, range 250 to 2,000)
Study: 8800113
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of high dose furosemide (equal dosage to infusion)
Study: 8800113
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of high dose furosemide
Study: 8800113
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of high dose furosemide
Study: 1624171
Drug: High glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High glycine amino acid solution (23% glycine nitrogen)
Study: 1624171
Drug: Low glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low glycine amino acid solution (4% glycine nitrogen)
Study: 1624171
Drug: High glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High glycine amino acid solution (25% glycine nitrogen)
Study: 1624171
Drug: Low glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low glycine amino acid solution (8% glycine nitrogen)
Study: 30654297
Drug: pembrolizumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab + CC-486
Study: 19158225
Drug: DHA oil
Normalized name: Ulkenia DHA oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA oil (7.5 g/d, 3 g DHA/d)
Study: 12607378
Drug: Web based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web based IT solutions for studies and registers
Study: 12607378
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of web based IT solutions
Study: 10979879
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (200 mg/wk)
Study: 10979879
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance training (three times weekly)
Study: 8780431
Drug: Inositol (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol (18 g/day)
Study: 1467134
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg BAY u 3405
Study: 1467134
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BAY u 3405
Study: 27814306
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy for 30 minutes followed by treadmill training only for 30 minutes
Study: 17453688
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg
Study: 17453688
Drug: Leuprolide 3.75
Normalized name: leuprolide 3.75 mg intramuscular powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide 3.75 mg
Study: 18685605
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea infusion
Study: 10787075
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (low dose intravenous epirubicin 20 mg/m2 and mitomycin 5 mg monthly for seven courses starting 5 to 6 weeks after surgery)
Study: 8857631
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (i.v.)
Study: 30299473
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (simvastatin)
Study: 29730268
Drug: Bilateral thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral thoracic paravertebral block at T8 with an infusion of 0.2% ropivacaine
Study: 29730268
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia at T7/8 with an infusion of 0.125% bupivacaine with hydromorphone 6 μg/mL
Study: 26583966
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume training (2 sets of 5 repetitions, twice a week)
Study: 26583966
Drug: Moderate volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate volume training (4 sets of 5 repetitions, twice a week)
Study: 18366642
Drug: Hypertension (BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertension (BP > or = 140/90 mmHg and/or treatment)
Study: 18366642
Drug: Diabetes (fasting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes (fasting plasma glucose > or = 7 mmol/l and/or treatment)
Study: 9592303
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1,000 mg twice daily for 1 week
Study: 9592303
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1,000 mg twice daily for 2 weeks
Study: 9592303
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate 240 mg twice daily, amoxicillin 1,000 mg twice daily, metronidazole 400 mg twice daily for 2 weeks
Study: 1872348
Drug: Multiple choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple choice response format (oral and written)
Study: 1872348
Drug: Usual history
Normalized name: histolyn CYL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual history question (oral and written)
Study: 31771375
Drug: Controller medication
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controller medication use (≥8 days over 2 weeks)
Study: 31487819
Drug: Native whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native whey (20 g, 2 servings daily)
Study: 31487819
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein (20 g, 2 servings daily)
Study: 8118992
Drug: Plasma spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma spray cementless THR (Mallory‐Head)
Study: 2563606
Drug: Acitretin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (40 mg daily for 4 weeks, then individually adjusted for 8 weeks)
Study: 2563606
Drug: Etretinate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate (40 mg daily for 4 weeks, then individually adjusted for 8 weeks)
Study: 1100535
Drug: Demetrin 3
Normalized name: Kevetrin
DrugBank: 4-isothioureidobutyronitrile (DB13010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demetrin 3 x 10 mg/day
Study: 1100535
Drug: Demetrin 3
Normalized name: Kevetrin
DrugBank: 4-isothioureidobutyronitrile (DB13010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demetrin 3 x 20 mg/day
Study: 26702086
Drug: Statewide public
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statewide public and health professional awareness campaign to increase regular aspirin use
Study: 21521834
Drug: Pantoprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (80 mg daily) administered concomitantly (CONC)
Study: 21521834
Drug: Pantoprazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (80 mg daily) administered staggered by 8 to 12 hours (STAG)
Study: 8951937
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tolperisone hydrochloride
Study: 12935797
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg pridinol mesilate
Study: 8603261
Drug: Thalidomide treatment
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide treatment (n=16)
Study: 8603261
Drug: Thalidomide treatment
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide treatment in patients with HIV‐1 and tuberculosis infections
Study: 8603261
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n=16)
Study: 8603261
Drug: Thalidomide treatment
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide treatment in patients with HIV‐1 infection only
Study: 1584941
Drug: Amebicidal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amebicidal therapy coupled with image-guided percutaneous therapeutic aspiration
Study: 1584941
Drug: Amebicidal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amebicidal therapy alone
Study: 27506585
Drug: Acetaminophen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (500 mg/8 h) over 6 weeks
Study: 27506585
Drug: Intra-articular leukocyte-poor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular leukocyte-poor PRP (LP-PRP) injections (three injections, once every 2 weeks)
Study: 18591575
Drug: Dextroamphetamine (d-amph)
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (d-amph) 10 mg single dose
Study: 12060506
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg single dose of itraconazole
Study: 12060506
Drug: 7-day 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day 200 mg daily dose of itraconazole
Study: 10221945
Drug: Counselling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselling and emotional support (combined with active drug)
Study: 10221945
Drug: Counselling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselling and emotional support (simple psychological treatment)
Study: 7884414
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (4 cycles of chemotherapy for 3 months before surgery followed by 4 cycles after surgery)
Study: 7884414
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (8 cycles of chemotherapy over 6 months after surgery)
Study: 375459
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus anticoagulants
Study: 27373329
Drug: Bet v
Normalized name: immunoglobulin G4-kappa, anti-[Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bet v 1 COPs 50 μg
Study: 27373329
Drug: Bet v
Normalized name: immunoglobulin G4-kappa, anti-[Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bet v 1 COPs 100 μg
Study: 17653314
Drug: Singulair 4
Normalized name: Singulair 4mg Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Singulair 4 mg once daily for 12 weeks
Study: 17653314
Drug: Budesonide aerosol
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aerosol 200 ug once or twice daily for 12 weeks
Study: 10069193
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg, once daily for 8 weeks)
Study: 1663226
Drug: Morphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.3 mg/kg bodyweight)
Study: 7128670
Drug: Terbutaline 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 0.125 mg and 0.250 mg via pressurized aerosol with pear-shaped spacer
Study: 7128670
Drug: Terbutaline 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 1.25 mg and 2.50 mg via nebulized solution
Study: 7128670
Drug: Initial placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial placebo treatment for both groups
Study: 31274152
Drug: Electrically guided
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrically guided LV lead placement with post-implant VVd optimization
Study: 29049868
Drug: Intense intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense intervention group (home-based assessments at 6-month intervals and a 12-month multidisciplinary program with weekly group sessions)
Study: 24397584
Drug: saxagliptin +
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saxagliptin + metformin
Study: 24397584
Drug: glipizide +
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glipizide + metformin
Study: 22809843
Drug: Aspirin resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin resistance defined by response to arachidonic acid after 3, 5 and 7 minutes (approximately 30% of patients)
Study: 22809843
Drug: Aspirin resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin resistance defined by response to adenosine diphosphate after 3 minutes (approximately 17% of patients)
Study: 22809843
Drug: Aspirin resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin resistance (49 patients)
Study: 22809843
Drug: Aspirin resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin resistance in patients with greatest renal disease